SAFE's participation in "Targeting and Cytotoxicity of Chimeric Antigen Receptor T Cells Transplanted with PD1 Extramembrane Structural Domains" is officially in press

Oct.10 2023

September 30th, 2023,Dr. Quanjun Wang, CEO and CSO of SAFE Pharmaceutical Technology Co., Ltd, participated in a CGT scientific research as a corresponding author, "Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain" . The essay was officially published in the SCI ”Experimental Hematology & Oncology", with an impact factor of 10.9.